Please login to the form below
BeiGene
This page shows the latest BeiGene news and features for those working in and with pharma, biotech and healthcare.
Merck expands partnership with Zymeworks for multispecific antibodies
Chinese pharma BeiGene also owns the rights to Zanidatamab and ZW49 in a number of East Asian countries including China and South Korea as well as Australia and New Zealand.
Latest news
-
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma
Other treatment options for advanced MCL include BeiGene’s recently approved BTK inhibitor Brukinsa (zanubrutinib) and AbbVie/Johnson &Johnson’s established BTK inhibitor Imbruvica (ibrutinib).
-
Boehringer Ingelheim to manufacture first biologic in China under new reforms
The milestone was achieved thanks to Boehringer’s collaboration with Chinese pharma company BeiGene, which included Boehringer offering manufacturing capabilities to support the launch of its monoclonal antibody tislelizumab. ... Boehringer will
-
BeiGene’s Brukinsa misses the mark in head-to-head Imbruvica trial
Although, BeiGene has said that Brukinsa demonstrated numerically higher VGPR rates, and improvements in safety and tolerability compared to Imbruvica. ... meaningful responses for many patients,” said Jane Huang (pictured left), chief medical officer,
-
AstraZeneca’s Calquence impresses in previously untreated CLL
However, there is also new competition in the lymphoma market from newcomer BeiGene – the Chinese-drugmaker recently won approval in the US for its MCL therapy Brukinsa (zanubrutinib).
-
China updates drug reimbursement list, agrees price cuts
Meanwhile, China’s pharma industry is also making headway in the immunotherapy market, with drugmaker BeiGene recently claiming the first approval for a Chinese-developed drug in the US for its
More from news
Approximately 10 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Chinese biotech’s global ambitions
BeiGene says it as headed off any such concens by working with well-established pharma company and contract manufacturer Boehringer Ingelheim to manufacture its drug. ... Meanwhile, BeiGene is also looking to break into the still all-important US market.
-
Biopharma's Future: Made in China
The rise of Chinese biopharma. One home-grown pharma company which could replicate this accomplishment is Beijing-headquartered BeiGene. ... BeiGene’s CEO John Oyler told a Goldman Sachs recent conference that a Chinese biopharma sector was ready to
-
Deal Watch March 2017
In particular, the third largest deal of the month is a joint venture between the research-based biotechnology company, BeiGene, which focuses on immuno-oncology, and the Guangzhou Development District. ... The agreement, worth $330m, will build BeiGene
-
Deal Watch table for November 2013
BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.
More from intelligence
Approximately 2 fully matching, plus 2 partially matching documents found.
Latest appointments
-
New hires at EMA, Gilead and BeiGene
EMA gains a new executive director, Gilead appoints a new senior vice president and BeiGene hires a new chief business exec. ... BeiGene. BeiGene has appointed Angus Grant (pictured above) as chief business executive.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- Roche’s Ocrevus boasts positive long-term data in MS
- Leadership change within Bedrock Group
- Lilly starts large-scale trial of tirzepatide in diabetic heart disease
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- OPEN Health’s Learning & Development team have won a Bronze Award at the PM Society Digital Awards 2020
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
PMHub
Syneos Health™
Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
